| [1] |
Hunger SP,Mullighan CG. Acute lymphoblastic leukemia in children[J]. N Engl J Med, 2015,373(16):1541-1552.
|
| [2] |
Brüggemann M,Raff T,Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia[J]. Blood, 2006,107(3):1116-1123.
|
| [3] |
Pui CH,Campana D,Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation[J]. N Engl J Med, 2009,360(26):2730-2741.
|
| [4] |
Faderl S,O′Brien S,Pui CH, et al. Adult acute lymphoblastic leukemia: concepts and strategies[J]. Cancer, 2010,116(5):1165-1176.
|
| [5] |
Campana D,Neale GA,Coustan-Smith E, et al. Detection of minimal residual disease in acute lymphoblastic leukemia: the St Jude experience[J]. Leukemia, 2001,15(2):278–279.
|
| [6] |
Weir EG,Cowan K,LeBeau P, et al. A limited antibody panel can dis-tinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection[J]. Leukemia, 1999,13(4):558-567.
|
| [7] |
Campana D. Minimal residual disease monitoring in childhood acute lymphoblastic leukemia[J]. Curr Opin Hematol, 2012,19(4):313-318.
|
| [8] |
Pui CH,Pei D,Coustan-Smith E, et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a pro-spective study[J]. Lancet Oncol, 2015,16(4):465-474.
|
| [9] |
Conter V,Bartram CR,Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study[J]. Blood, 2010,115(16):3206-3214.
|
| [10] |
Coustan-Smith E,Sancho J,Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia[J]. Blood, 2000,96(8):2691-2696.
|
| [11] |
Coustan-Smith E,Ribeiro RC,Stow P, et al. A simplified flow cytometric assay identifies children with acute lymphoblastic leu-kemia who have a superior clinical outcome[J]. Blood, 2006,108(1):97-102.
|
| [12] |
Schrappe M,Valsecchi MG,Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study[J]. Blood, 2011,118(8):2077-2084.
|
| [13] |
Gaipa G,Basso G,Biondi A, et al. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia[J]. Cytometry B Clin Cytom, 2013,84(6):359-369.
|
| [14] |
Tomová A,Babusiková O. Shifts in expression of immunological cell markers in relapsed acute leukemia[J]. Neoplasma, 2001,48(3):164-168.
|
| [15] |
Hur M,Chang YH,Lee DS, et al. Immunophenotypic and cyto-genetic changes in acute leukaemia at relapse[J]. Clin Lab Haematol, 2001,23(3):173-179.
|
| [16] |
Coustan-Smith E,Behm FG,Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia[J]. Lancet, 1998,351(9102):550-554.
|
| [17] |
Baer MR,Stewart CC,Dodge RK, et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)[J]. Blood, 2001,97(11):3574-3580.
|
| [18] |
Abshire TC,Buchanan GR,Jackson JF, et al. Morphologic, immunologic and cytogenetic studies in children with acute lym-phoblastic leukemia at diagnosis and relapse: a Pediatric Oncology Group study[J]. Leukemia, 1992,6(5):357-362.
|
| [19] |
Guglielmi C,Cordone I,Boecklin F, et al. Immunophenotype of adult and childhood acute lymphoblastic leukemia: changes at first relapse and clinico-prognostic implications[J]. Leukemia, 1997,11(9):1501-1507.
|
| [20] |
Bennet JM,Catovsky D,Daniel MT, et al. The morphological classification of acute lymphoblastic leukemia: concordance among observers and clinical correlation[J]. Br J Haematol, 1981,47(4):553-561.
|
| [21] |
Lucio P,Gaipa G,van Lochem EG, et al. BIOMED-I concerted action report: flow cytometric im-munophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 concerted action investigation of minimal residual disease in acute leukemia: in-ternational standardization and clinical evaluation[J]. Leukemia, 2001,15(8):1185-1192.
|
| [22] |
Wang Y,Peng L,Dai Q, et al. Clinical value to quantitate hematogones in Chinese childhood acute lymphoblastic leukemia by flow cytometry analysis[J]. Int J Lab Hematol, 2016,38(3):246-255.
|
| [23] |
Bayram I,Erbey F,Kömür M, et al. Flow cytometry results at diagnosis and relapse in childhood acute lymphoblastic leukemia[J]. Asian Pac J Cancer Prev, 2010,11(5):1321-1324.
|
| [24] |
Campana D,Coustan-Smith E,Janossy G. The immunologic detection of minimal residual disease in acute leukemia[J]. Blood, 1990,76(1):163-171.
|
| [25] |
Borowitz MJ,Pullen DJ,Winick N, et al. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children′s oncology group[J]. Cytometry B Clin Cytom, 2005,68(1):18-24.
|
| [26] |
Van Wering ER,Beishuizen A,Roeffen ET, et al. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia[J]. Leukemia, 1995,9(9):1523-1533.
|
| [27] |
Burnusuzov HA,Spasova MI,Murdjeca MA, et al. Immunophenotypic modulation of the blast cells in childhood acute lymphoblastic leukemia minimal residual disease detection[J]. Folia Med, 2016,58(1): 28-35.
|
| [28] |
Gaipa G,Basso G,Maglia O, et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal re-sidual disease detection[J]. Leukemia, 2005,19(1):49-56.
|
| [29] |
Dworzak MN,Schumich A,Printz D, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leu-kemia during induction treatment: setting the stage for anti-CD20 directed im-munotherapy[J]. Blood, 2008,112(10):3982-3988.
|
| [30] |
Slamova L,Starkova J,Fronkova E, et al. CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage[J]. Leukemi, 2013,28(2014):609-620.
|
| [31] |
Vidriales MB,Pérez JJ,López-Berges MC, et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value[J]. Blood, 2003,101(12):4695-4700.
|
| [32] |
Gökbuget N,Hoelzer D. Recent approaches in acute lymphoblastic leukemia in adults[J]. Rev Clin Exp Hematol, 2002,6(2):114-141.
|
| [33] |
Thomas X,Danaïla C,Le QH, et al. Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period[J]. Leukemia, 2001,37(12):1811-1822.
|
| [34] |
Verma A,Stock W. Management of adult acute lymphoblastic leukemia: moving toward a riskadapted approach[J]. Curr Opin Oncol, 2001,13(1):14-20.
|
| [35] |
Schultz KR,Pullen DJ,Sather HN, et al. Risk- and response-based classification of childhood B-precursor acute lympho-blastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children′s Cancer Group (CCG)[J]. Blood, 2007,109(3):926-935.
|
| [36] |
Aricò M,Valsecchi MG,Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. N Engl J Med, 2000,342(14):998-1006.
|
| [37] |
Pieters R. Infant acute lymphoblastic leukemia: lessons learned and future direc-tions[J]. Curr Hematol Malig Rep, 2009,4(3):167-174.
|
| [38] |
Gao C,Zhao XX,Li WJ, et al. Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1004 patients[J]. Am J Hematol, 2012,87(11):1022-1027.
|
| [39] |
Teachey DT,Hunger SP. Predicting relapse risk in childhood acute lymphoblastic leukaemia[J]. Br J Haematol, 2013,162(5):606-620.
|
| [40] |
Aricò M,Schrappe M,Hunger SP, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-po-sitive acute lymphoblastic leukemia treated between 1995 and 2005[J]. J Clin Oncol, 2010,28(31):4755-4761.
|